The global coronary stents market is witnessing steady expansion, driven by rising cardiovascular disease prevalence, technological advancements, and wider access to interventional cardiology procedures. According to Persistence Market Research, the market is projected to grow from US$ 10.2 billion in 2025 to US$ 15.7 billion by 2032, registering a CAGR of 6.4% during the forecast period. Drug-eluting stents (DES) remain the dominant product type, accounting for nearly 67.5% share in 2025, owing to their ability to reduce restenosis rates.
North America leads the global market with an estimated 44.2% share in 2025, backed by advanced healthcare infrastructure, strong reimbursement frameworks, and early adoption of novel technologies. Europe is the fastest-growing region, propelled by favorable regulatory approvals and increasing adoption of next-generation stents. The Asia Pacific region, particularly China and India, is also emerging as a key market due to large patient volumes, government procurement programs, and affordability measures.
Key Highlights from the Report:
• Global coronary stents market projected to reach US$ 15.7 Bn by 2032 at 6.4% CAGR.
• North America leads with 44.2% share in 2025, supported by advanced infrastructure and reimbursement.
• Drug-eluting stents dominate with 67.5% market share in 2025 due to superior efficacy.
• Outpatient facilities hold 58.3% share in 2025, driven by advancements in PCI and same-day discharge trends.
• Europe emerges as the fastest-growing market with favorable regulatory pathways for next-generation stents.
• Paclitaxel-coated balloons show promising results in reducing restenosis in complex cases.
Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/3275
Market Segmentation:
Product Type Insights
The market is segmented into Bare Metal Stents (BMS), Drug-Eluting Stents (DES), and Bioresorbable Vascular Scaffolds (BVS). Among these, DES dominate with approximately 67.5% share in 2025, thanks to their proven ability to release antiproliferative drugs that significantly reduce restenosis rates. Clinical trials consistently show that DES reduce repeat interventions, positioning them as the gold standard in interventional cardiology.
Meanwhile, bioresorbable stents are attracting increasing interest due to their ability to provide temporary vessel scaffolding before dissolving. This feature restores natural vessel flexibility and minimizes long-term complications such as thrombosis. These stents are especially promising for younger patients who may require multiple interventions throughout their lifetime.
End-user Insights
By end-user, the market is bifurcated into inpatient facilities and outpatient facilities. Outpatient centers dominate with nearly 58.3% share in 2025, driven by minimally invasive PCI procedures and advanced DES technologies that enable safe same-day discharge. This shift not only enhances patient experience but also reduces healthcare costs.
Inpatient facilities, however, continue to play a crucial role in managing complex, high-risk cases requiring extended monitoring. Patients with multiple comorbidities or severe coronary blockages often need intensive post-procedural care, which supports steady demand in this segment, particularly in aging populations like Japan and parts of Europe.
Regional Insights:
North America
North America holds the leading position in the global market, accounting for 44.2% share in 2025. The U.S. drives growth with high PCI volumes, rapid adoption of DES, and new approvals such as the Agent Coronary Drug-Coated Balloon. Strong reimbursement support further strengthens regional dominance.
Europe
Europe is the fastest-growing region, driven by favorable regulatory approvals and the introduction of devices tailored for complex cases. Innovative technologies such as Biotronik’s Orsiro Mission DES and Elixir’s DynamX bioadaptor highlight the region’s focus on advanced, patient-specific solutions.
Asia Pacific
Asia Pacific demonstrates rapid growth, with China leading due to government procurement initiatives and local manufacturing dominance. India benefits from affordability measures such as government price caps, while Japan sees strong adoption due to its aging population and universal healthcare system.
Market Dynamics:
Market Drivers
The most significant driver is the rising prevalence of Coronary Artery Disease (CAD) worldwide, fueled by aging populations, unhealthy lifestyles, and increasing rates of obesity and diabetes. Countries like China and India are experiencing surging demand due to dietary changes and growing healthcare access. In the U.S., CAD affects over 20 million adults, ensuring sustained demand for coronary interventions.
Market Restraints
Product recalls and safety concerns remain critical restraints. High-profile recalls, such as Medtronic’s voluntary recall of its Onyx Frontier stent in 2023 and Abbott’s earlier withdrawal of its Absorb BVS, have dented physician confidence. Such events not only delay adoption but also create skepticism toward newer technologies.
Market Opportunities
The future lies in 3D-printed personalized stents that address complex vessel anatomies. These allow for patient-specific designs, reducing complications and improving long-term outcomes. While still in early stages, collaborations such as those at ETH Zurich demonstrate strong potential for commercial adoption once regulatory frameworks evolve.
Reasons to Buy the Report:
Comprehensive analysis of global coronary stents market dynamics and growth opportunities.
Detailed segmentation by product type, end-user, and region for strategic decision-making.
In-depth insights on regulatory trends and emerging innovations such as 3D-printed stents.
Coverage of competitive landscape with profiles of leading global and regional players.
Future outlook with forecast up to 2032 for investment and planning purposes.
Frequently Asked Questions (FAQs):
• How Big is the Coronary Stents Market?
• Who are the Key Players in the Global Coronary Stents Market?
• What is the Projected Growth Rate of the Coronary Stents Market?
• What is the Market Forecast for Coronary Stents by 2032?
• Which Region is Estimated to Dominate the Industry through the Forecast Period?
Company Insights:
Key Players
• Abbott Laboratories
• Boston Scientific Corporation
• MicroPort Scientific Corporation
• Terumo Corporation
• Stentys SA
• B Braun SE
• C. R. Bard, Inc.
• Biotronik
• Cook Medical
• Meril Life Sciences Pvt. Ltd.
• Biosensors International Group Limited
Recent Developments:
• In August 2025, the AGENT IDE trial subgroup analysis confirmed the effectiveness of paclitaxel-coated drug-coated balloons in reducing restenosis for multilayer stent patients.
• In May 2024, Abbott launched its XIENCE Sierra Everolimus-Eluting Coronary Stent System in India, strengthening its presence in emerging markets.
Conclusion:
The coronary stents market is entering a transformative phase, marked by sustained demand, continuous product innovation, and a clear shift toward patient-centered solutions. With the market expected to rise from US$ 10.2 billion in 2025 to US$ 15.7 billion by 2032, opportunities are abundant for companies that can balance safety, efficacy, and affordability. North America will continue to lead adoption, while Europe and Asia Pacific are set to accelerate growth through regulatory support and healthcare expansion.
Challenges such as product recalls and safety concerns remain, but they are being countered by technological breakthroughs like drug-coated balloons, bioresorbable scaffolds, and 3D-printed stents. Outpatient facilities are reshaping treatment pathways by enabling same-day discharges, cutting costs, and improving patient experiences. With rising cardiovascular disease prevalence worldwide, coronary stents are not only becoming more accessible but also more advanced, ensuring better outcomes for millions of patients.
Read Related Reports:
